Fluoresentric Sets Sights on Point-of-Care Dx With New Instrument Subsidiary | GenomeWeb

NEW YORK (GenomeWeb) – It's been a long and winding road for Fluoresentric's proprietary DNA amplification technology, but the firm is hoping that road will lead to the potentially lucrative point-of-care diagnostics market.

The Park City, Utah-based firm said this week that it is launching a new subsidiary to make portable hand-held instruments to run infectious disease assays based on its proprietary chemistry in pharmacies, retail clinics, warehouses, and anyplace where molecular diagnostics has yet to find widespread use.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Sponsored by

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.